Find a Clinical Trial

Showing 121 - 130 of 168 Trials

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06561685

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...
A MULTICENTER, OPEN-LABEL PHASE 1/1B/PHASE 2DOSE-FINDING, SAFETY, AND PHARMACOKINETICSTUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYLAURISTATIN E (MMAE) ANTIBODY DRUGCONJUGATE, IN ADVANCED REFRACTORYSOLID TUMORS

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06014658

Population:

Adult

Phase:

I

The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...
A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial)

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06625775

Population:

Adult

Phase:

I

The purpose of this study is to find the best dose and effects of BBO-10203 when used alone or in combination with Trastuzumab in HER2-positive advanced breast cancer (aBC) or HR- positive, HER2-negative aBC or advanced non-small cell lung cancer (aNSCLC) with a KRAS (Kirsten rat sarcoma) mutation or advanced colorectal cancer (aCRC) with a KRAS mutation.BBO-10203 has not been approved by the Food and Drug Administration (FDA). Trastuzumab is FDA approved but not in combination with BBO-10203. This is a first in human study. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older...
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD6008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation (TIAN-SHAN1)

Principal Investigator:

Catherine Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06813365

Population:

Adult

Phase:

I

This study is a Phase 1 clinical trial, which means it is the first stage of testing a new drug in humans to evaluate its safety, determine how the body processes it, and identify any potential side effects. The drug being studied, DZD6008, is investigational, meaning it has not been approved by the U.S. Food and Drug Administration (FDA). This study is evaluating the study drug, DZD6008, in patients with advanced non small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. EGFR is a protein that is important in regulating activities in cell proliferation...
A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced HepatocellularCarcinoma and Other Solid Tumors with Activating FGF/FGFR pathway aberrations (SURF-431)

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06915753

Population:

Adult

Phase:

I

The purpose of this Study is to find out if an investigational drug, TYRA-430, is safe and effective at treating cancer in participants with locally advanced/metastatic liver cancer and other solid tumors tumors that have a certain mutation or alteration of a type of protein located on the surface of cancer cells. Investigational drug means that it has not been approved by the United States Food and Drug Administration (US FDA) to use or to treat any disease or cancer. This is the first time that the Study Drug has been used in people. Are you Eligible? (Inclusion Criteria) 18 years of age or...
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06917079

Population:

Adult

Phase:

I

The purpose of this study is to find the best dose of the study drug, BBO-11818, when used alone (single therapy) and in combination with other standard of care treatments, and to see what effects, good or bad, the study drug has on participants. While the standard of care treatments, pembrolizumab, pemetrexed, cisplatin, carboplatin, and cetuximab are FDA-approved individually, the combination of BBO-11818 with these treatments is considered experimental. The study drug, BBO-11818, has not been approved by the U.S. Food and Drug Administration (FDA). This is the first time that BBO- 11818...
A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT07082920

Population:

Adult

Phase:

I

The purpose of this study is to find a safe dose of investigational study drug, JNJ- 95298177 when given in combination with investigational drug, JNJ-78278343 in patients with prostate cancer. JNJ-78278343 and JNJ-95298177 are not approved by the United States Food and Drug Administration (FDA). The sponsor, Janssen Research & Development, provides the investigational study treatment, called “JNJ-78278343 and JNJ-95298177”. This is the first time that JNJ-78278343 is being used in combination with JNJ-95298177. Are you Eligible? (Inclusion Criteria) At the time of informed...
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Efficacy of YL217 in Patients with Advanced Solid Tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06859762

Population:

Adult

Phase:

I

The main purpose of this study is to evaluate the safety and effectiveness of the study drug, YL217, in different solid tumor types. We also want to learn: ● The dosage of YL217 that can be safely given to humans ● What effect (good or bad) YL217 has on your cancer ● What happens to YL217 once it is in your body (so called pharmacokinetics; PK) ● What YL217 does to your body MediLink Therapeutics has begun a study of an investigational drug (also known as the “study drug”) called YL217 as a possible treatment for CDH17 expressed solid tumors. CDH17 is a type of protein found on...
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy ofLY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing TumorCells, in Participants with Selected Advanced Solid Tumors

Principal Investigator:

Lanyi Nora Chen, MD

Contact Number:

212-342-5162

NCT Number:

NCT07046923

Population:

Adult

Phase:

I

The purpose of this study is to learn about the effects of the study drug, LY4175408, to find the best dose for treating advanced/metastatic (meaning the cancer has spread beyond where it started to other parts of the body) cancers and to see how safe LY4175408 is for patients with advanced/metastatic cancers. LY4175408 is an “investigational” drug in this study because it has not been approved by The United States Food and Drug Administration (FDA), the health authority that gives approval for new medicines in the United States. Are you Eligible? (Inclusion Criteria) Is ≥18...
A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Principal Investigator:

Peter Chei-Way Pan, MD

Contact Number:

212-342-5162

NCT Number:

NCT06860594

Population:

Adult

Phase:

I

Researchers recently found that triapine can make radiation therapy work better against glioblastoma cells and in mice with glioblastoma. Tumors did not grow for a longer time after treatment with triapine along with radiation compared to radiation alone. Triapine has also been tested in people with other types of cancers and has been found to be safe. This study is being done to answer the following question: What is the highest dose of triapine that can be safely and tolerably taken in combination with radiation therapy in patients with recurrent glioblastoma or astrocytoma? We are doing...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages